Curasen Logo
  • About
  • Leadership
  • Science
  • Careers
  • News
  • Contact

News

  • About
  • Leadership
  • Science
  • Careers
  • News
  • Contact

Please click on the links below to read the latest news releases from CuraSen.

November 9, 2021

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

View Release

March 15, 2021

CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease

View Release

September 15, 2020

CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease

View Release

September 10, 2019

CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations

View Release

November 1, 2018

CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer

View Release

October 14, 2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases

View Release

© 2022 by CuraSen Therapeutics, Inc.
MENU
  • About
  • Leadership
  • Science
  • Careers
  • News
  • Contact